Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

Quest Diagnostics reported Q2 2026 net revenues of $3.04B (+10.2% y/y) and diluted EPS of $2.84 (+15.0% y/y), with adjusted diluted EPS rising 19.1% to $3.12. The company raised full-year 2026 guidance to $11.95B–$12.05B in revenues and GAAP diluted EPS of $9.97–$10.17 (adjusted EPS $11.05–$11.25). Cash from operations was $597M (+9.7% y/y) and capex increased to $138M (+27%). Management cited strong organic growth (10.0% organic revenue growth) and sustained demand, supported by expanded testing/automation and new platform integrations.

Analysis

The key market takeaway is not the beat itself but that Quest is converting above-trend volume into earnings while still taking some price pressure. That combination usually means utilization is running hot enough to offset reimbursement drag and fixed-cost leverage is still positive, which is the opposite of the late-cycle deterioration the market feared for large lab names. It also makes the stock a cleaner cash-return story: buybacks and FCF should mechanically support EPS even if core pricing stays soft.

Relative winners are DGX versus both hospital-based lab models and smaller specialty diagnostics players. Quest’s automation and front-end workflow tools create a subtler second-order effect: they raise switching costs for physicians/hospitals by reducing specimen friction, which can quietly pressure Labcorp’s share gains in the same channels over the next 1-3 quarters. The caution is that the “advanced diagnostics” narrative may be overstated near term; most of the earnings power still comes from routine testing volume, not from new assay launches.

The contrarian risk is that management’s revenue growth could be partially flattered by transient ordering strength, while the continued decline in revenue per requisition signals that mix and pricing are not structurally improving. If volume normalizes, operating leverage can reverse quickly because this is still a high-fixed-cost network business. Over 6-18 months, the thesis is only durable if Quest keeps converting automation into margin expansion and not just top-line growth.

Key Decisions for Investors

• Long DGX on any 1-2 day post-earnings pullback; use a 3-6 month horizon and look for follow-through if the market revises FY26 EPS upward after the call. Falsify on any guide cut or a sustained deceleration in requisition growth below high single digits.
• Pair trade: long DGX / short LH for 1-3 months. The spread should work if Quest’s workflow automation continues to protect margins while Labcorp remains more exposed to pricing and integration friction.
• If DGX rallies hard on the print, fade part of it via covered call writing or a tighter stop rather than adding aggressively. The upside from a good quarter is likely smaller than the downside if volume growth proves transitory.
• Watch for a follow-on catalyst in AONC/oncology adoption and Flatiron integration over the next 2-3 quarters; if external evidence shows payer or channel uptake, reassess DGX as a longer-duration quality compounder.
• Relative value alert: own DGX versus XLV on the thesis that diagnostics execution is more idiosyncratic and less rate-sensitive than the broader managed-care / provider complex over the next 6-12 months.